1. Introduction {#sec1-ijerph-13-01142}
===============

Diabetic retinopathy(DR) is the premier cause of vision loss in adults aged 20--74 years \[[@B1-ijerph-13-01142]\]. From 1990 to 2010, DR ranked as the fifth most accpeted cause of preventable blindness and moderate to severe visual impairment \[[@B2-ijerph-13-01142]\]. Diabetic retinopathy (DR) is a microvascular complication occurring both in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and it was estimated that, of 285 million people worldwide with diabetes, over one-third had signs of DR in 2010 \[[@B3-ijerph-13-01142]\]. DR is a complex trait involving polygenic, metabolic, and environmental influences. Known risk factors, most notably the duration of diabetes and glycemic control, explain some, but not all, of the progression of DR \[[@B4-ijerph-13-01142],[@B5-ijerph-13-01142],[@B6-ijerph-13-01142]\]. There are diabetic patients with DR despite short durations of diabetes and/or perfect glycemic control and other diabetic patients who do not develop DR in the face of long-standing diabetes and/or long-term hyperglycemia \[[@B7-ijerph-13-01142]\]. Therefore, the genetic factor may explain some of the variation in the progression of DR \[[@B8-ijerph-13-01142]\].

The angiotensin-converting enzyme (ACE) gene, plays an critical role in modulating vascular tone through hydrolyzing angiotensin I to vasoconstrictory peptide angiotensin II, which seems to be particularly biologically and clinically relevant to diabetes \[[@B9-ijerph-13-01142]\]. A number of studies have reported that patients suffering from DR have high circulating levels of ACE, which implies that elevated serum ACE levels might be a possible hazard factor in destroying retinal vascular apparatus in subjects suffering from diabetes \[[@B10-ijerph-13-01142]\]. The ACE gene has a frequent insertion/deletion (I/D) polymorphism characterized by the presence or absence of a 287 bp Alu repetitive sequence in intron 16 \[[@B11-ijerph-13-01142]\]. This polymorphism was associated with circulating ACE levels and increased plasma and tissue activity of this enzyme \[[@B11-ijerph-13-01142],[@B12-ijerph-13-01142],[@B13-ijerph-13-01142]\]. Because of the central role of the ACE gene, it is feasible to hypothesize that polymorphism of *ACE* I/D contributes to the development of DR and numerous studies have addressed the role of the variation in the complex etiology of DR.

Numbers of molecular epidemiological studies have been performed to examine the relationship between the *ACE* I/D polymorphism and DR \[[@B14-ijerph-13-01142],[@B15-ijerph-13-01142],[@B16-ijerph-13-01142],[@B17-ijerph-13-01142],[@B18-ijerph-13-01142],[@B19-ijerph-13-01142],[@B20-ijerph-13-01142],[@B21-ijerph-13-01142],[@B22-ijerph-13-01142],[@B23-ijerph-13-01142],[@B24-ijerph-13-01142],[@B25-ijerph-13-01142],[@B26-ijerph-13-01142],[@B27-ijerph-13-01142],[@B28-ijerph-13-01142],[@B29-ijerph-13-01142],[@B30-ijerph-13-01142],[@B31-ijerph-13-01142],[@B32-ijerph-13-01142],[@B33-ijerph-13-01142],[@B34-ijerph-13-01142],[@B35-ijerph-13-01142],[@B36-ijerph-13-01142],[@B37-ijerph-13-01142],[@B38-ijerph-13-01142],[@B39-ijerph-13-01142],[@B40-ijerph-13-01142],[@B41-ijerph-13-01142],[@B42-ijerph-13-01142],[@B43-ijerph-13-01142],[@B44-ijerph-13-01142],[@B45-ijerph-13-01142],[@B46-ijerph-13-01142],[@B47-ijerph-13-01142],[@B48-ijerph-13-01142],[@B49-ijerph-13-01142],[@B50-ijerph-13-01142],[@B51-ijerph-13-01142],[@B52-ijerph-13-01142],[@B53-ijerph-13-01142],[@B54-ijerph-13-01142],[@B55-ijerph-13-01142]\], but the results remain inconclusive. Although several meta-analyses have been published \[[@B56-ijerph-13-01142],[@B57-ijerph-13-01142]\], they still did not reach a consistent conclusion. To better shed light on these conflicting findings and to quantify the potential between-study heterogeneity and provide better ability to detect smaller effect sizes, we conducted a comprehensive meta-analysis on 40 published studies from 1994 to 2016 with 4252 diabetic retinopathy cases and 5916 controls relating the variant of the *ACE* I/D polymorphism to the risk of developing DR.

2. Methods {#sec2-ijerph-13-01142}
==========

This study was reported according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for reporting systematic reviews and meta-analyses. Study selection, data extraction, and quality assessment were completed independently by two investigators. Disagreement was resolved through discussion. If the discussion did not lead to a consensus, Professor Wu made the final decision.

2.1. Identification and Eligibility of Relevant Studies {#sec2dot1-ijerph-13-01142}
-------------------------------------------------------

All studies that determined the genotype distribution of *ACE* I/D polymorphism in cases with diabetes retinopathy, and (i) in diseased controls (subjects with diabetes and free of DR) or (ii) in healthy controls, were attempted to be included in the meta-analysis. Cases were type 1 or 2 diabetic subjects with background, simple, advanced, or proliferative DR. The control group consisted of two subgroups, the first was the diseased control group, which consisted of subjects with diabetes and which were free of diabetic retinopathy disease, i.e., diabetes nephropathy and myocardial infarct, and the second group was the healthy controls, which was made up of subjects without any diseases.

Studies were firstly identified by searching the electronic literature PubMed for relevant reports in English and CNKI for papers in Chinese (from January 1994 to April 2016, using the search terms "angiotensin converting enzyme" or "ACE" or "rs1799752" in combination with "diabetic retinopathy" or "diabetic retinopathies" or "DR"). We chose articles which were conducted among human subjects. Eligible studies were then identified by further searching the studies published to date on the association between *ACE* I/D polymorphism and diabetic retinopathy risk, and restricted attention to the studies that satisfied all of the following criteria: studies related to the ACE polymorphism were determined regardless of sample size and study design (case-control, cross-sectional, or cohort studies); each genotype frequency was reported, and there was sufficient information for extraction of data; if studies had partly overlapped subjects, only the one with a larger and/or the latest sample size was selected for the analysis. Additional studies were identified by hands-on searches from references of original studies or review articles on this topic. According to these criteria, we finally included 40 papers in our meta-analysis.

2.2. Data Extraction and Conversion {#sec2dot2-ijerph-13-01142}
-----------------------------------

Two investigators independently extracted data and reached a consensus on all of the items. Data extracted from these articles included the first author's name, year of publication, study design, ethnicity of the study population, type of DM, clinical characteristics, and the number of cases and controls for *ACE* I/D genotypes. The frequencies of the alleles and the genotypic distributions were extracted or calculated for both cases and controls. We defined that diabetic patients without retinopathy and/or matched healthy persons constituted the control group, and patients with DR were the case group. We merged the original data into the control group or case group if the study did not provide corresponding data. For some studies without sufficient information for extraction of data, we tried to contact the studies' authors by sending emails to request data missing from their articles. In addition, it was tested whether the distribution of genotypes in the controls was consistent with the Hardy-Weinberg equilibrium (HWE) for each study, and calculated the frequency of the minor allele for *ACE* I/D polymorphism.

2.3. Quality Assessment and Study Stratification {#sec2dot3-ijerph-13-01142}
------------------------------------------------

The Newcastle-Ottawa scale (NOS) method was used to assess the observational included studies. The NOS is composed of three parts (8 entries): selection, comparability, and exposure. A quality item is given only one star for the study in selection and exposure, and a quality item is given, at most, two stars for the study in comparability. It is a semi-quantitative scale, and a score of 0--9 stars is assigned to each study. Studies whose scores were more than 6 stars were considered to be of relatively high quality \[[@B58-ijerph-13-01142]\]. The scores of included studies are shown in [Table 1](#ijerph-13-01142-t001){ref-type="table"}.

2.4. Meta-Analysis {#sec2dot4-ijerph-13-01142}
------------------

The meta-analysis evaluated the relationship between the *ACE* I/D polymorphism and the risk of DR for each study by odds ratio (OR), with 95% confidence intervals (95% CI). For all studies, we calculated the ORs for the: (i) separate pairwise comparisons; (ii) allele contrast; (iii) recessive model; and (iv) dominant model. In addition, we conducted stratification analysis by ethnicity and DM type. A sensitivity analysis, which examines the effect of excluding specific studies, was also performed \[[@B59-ijerph-13-01142]\]. Our meta-analysis was subjected to sensitivity analysis for studies with the controls not in HWE (*p* \< 0.05).

The χ^2^-based Q statistic test was used to assess the heterogeneity, and it was considered significant for *p* \< 0.05. Heterogeneity was quantified with the *I*^2^ metric, which is independent of the number of studies in the meta-analysis. *I*^2^ takes values between 0% and 100%, with higher values denoting a greater degree of heterogeneity (*I*^2^ \> 50% was considered significant) \[[@B60-ijerph-13-01142]\]. We used the fixed-effects model and the random-effects model based on the Mantel-Haenszel method and the DerSimonian and Laird method, respectively, to combine values from each of the studies. When the effects were assumed to be homogenous, the fixed-effects model was then used; otherwise, the random-effects model was more appropriate \[[@B61-ijerph-13-01142]\]. In addition, we further conducted meta-regression analyses to estimate the source of heterogeneity. Publication bias was assessed according to the Egger regression asymmetry test and the Begg adjusted rank correlation test \[[@B62-ijerph-13-01142],[@B63-ijerph-13-01142]\]. All analysis was done by using the Stata software (v.12.1) (StataCorp LP, College Station, TX, USA). All the *p* values were two-sided.

3. Results {#sec3-ijerph-13-01142}
==========

3.1. Literature Search {#sec3dot1-ijerph-13-01142}
----------------------

The study selection process is shown in [Figure 1](#ijerph-13-01142-f001){ref-type="fig"}. A total of 660 articles (PubMed 572, CNKI 88) were identified from the databases, and 0 duplicates were excluded, using EndNote (X7) (Thomson ResearchSoft, Stamford, CT, USA). In addition, 581 articles were excluded, based on a review of the titles and abstracts, and 79 full-text articles were assessed for eligibility; 37 articles were excluded due to various reasons, such as being review articles or case reports, being written in languages other than English or Chinese, or could not provide each genotype frequency or other sufficient information for extraction of data. Finally, a total of 40 \[[@B14-ijerph-13-01142],[@B15-ijerph-13-01142],[@B16-ijerph-13-01142],[@B17-ijerph-13-01142],[@B18-ijerph-13-01142],[@B19-ijerph-13-01142],[@B20-ijerph-13-01142],[@B21-ijerph-13-01142],[@B22-ijerph-13-01142],[@B23-ijerph-13-01142],[@B24-ijerph-13-01142],[@B25-ijerph-13-01142],[@B26-ijerph-13-01142],[@B27-ijerph-13-01142],[@B28-ijerph-13-01142],[@B29-ijerph-13-01142],[@B30-ijerph-13-01142],[@B31-ijerph-13-01142],[@B32-ijerph-13-01142],[@B33-ijerph-13-01142],[@B34-ijerph-13-01142],[@B35-ijerph-13-01142],[@B36-ijerph-13-01142],[@B37-ijerph-13-01142],[@B38-ijerph-13-01142],[@B39-ijerph-13-01142],[@B40-ijerph-13-01142],[@B41-ijerph-13-01142],[@B42-ijerph-13-01142],[@B43-ijerph-13-01142],[@B44-ijerph-13-01142],[@B45-ijerph-13-01142],[@B46-ijerph-13-01142],[@B47-ijerph-13-01142],[@B48-ijerph-13-01142],[@B49-ijerph-13-01142],[@B50-ijerph-13-01142],[@B51-ijerph-13-01142],[@B54-ijerph-13-01142],[@B55-ijerph-13-01142]\] articles were included in this meta-analysis.

3.2. Eligible Studies and Study Characteristics {#sec3dot2-ijerph-13-01142}
-----------------------------------------------

The selected study characteristics from the studies included in the meta-analysis are provided in [Table 1](#ijerph-13-01142-t001){ref-type="table"}, and the details on *ACE* I/D polymorphism allele/genotype prevalence are shown in [Table 2](#ijerph-13-01142-t002){ref-type="table"}. For 40 studies, 8 studies (7 Non-Asian, 1 Asian) involved cases with T1DM, 33 (9 Non-Asian, 24 Asian) with T2DM, and 1 study (\[[@B21-ijerph-13-01142]\])with un-defined DM type (1 Asian study with 100 cases and 164 controls). It is worth emphasizing that 2 studies (\[[@B17-ijerph-13-01142],[@B44-ijerph-13-01142]\]) involved both T1DM and T2DM. The studies on T1DM Non-Asians contributed 599 cases and 614 control subjects, while the Asian studies included 33 cases and 104 control subjects. Among the T2DM studies, studies involving Non-Asians contributed 865 cases and 1541 control subjects, while the Asian studies included 2655 cases and 3659 control subjects. Thirty-three studies were case-control study design, 4 studies were cross-sectional study design, and 3 studies were cohort study design.

3.3. Summary Statistics {#sec3dot3-ijerph-13-01142}
-----------------------

Data from 40 articles that investigated the association between the ACE I/D polymorphism and DR risk were included in the meta-analysis. The overall frequency (%) of minor D allele frequency (MAF) was 0.47/0.46 for cases and controls. The frequency of the MAF for each study polymorphism on controls is shown in [Table 1](#ijerph-13-01142-t001){ref-type="table"}. All studies suggested that the genotypes distribution in controls was consistent with the Hardy-Weinberg equilibrium except for 8 studies (\[[@B22-ijerph-13-01142],[@B28-ijerph-13-01142],[@B30-ijerph-13-01142],[@B35-ijerph-13-01142],[@B38-ijerph-13-01142],[@B43-ijerph-13-01142],[@B48-ijerph-13-01142],[@B51-ijerph-13-01142]\]), indicating genotyping errors and/or population stratification \[[@B59-ijerph-13-01142]\]; therefore, a sensitivity analysis was performed by excluding these studies.

3.4. Main Results, Stratification, and Sensitivity Analyses {#sec3dot4-ijerph-13-01142}
-----------------------------------------------------------

The estimation of the relationship of *ACE* I/D polymorphism with DR is presented in [Table 3](#ijerph-13-01142-t003){ref-type="table"}. [Figure 2](#ijerph-13-01142-f002){ref-type="fig"} shows the overall effect for the relationship between the polymorphism and the DR risk in dominant model.

As shown in [Table 3](#ijerph-13-01142-t003){ref-type="table"}, the overall analysis found a significant association between the ACE I/D polymorphism and the risk of DR for all genetic models (ID vs. II: OR = 1.14, 95% CI: 1.00--1.30; DD vs. II: OR = 1.38, 95% CI: 1.11--1.71; Allele contrast: OR = 1.17, 95% CI: 1.05--1.30; recessive model: OR = 1.24, 95% CI: 1.02--1.51 and dominant model: OR = 1.21, 95% CI: 1.06--1.38, respectively).

In a stratified analysis by ethnicity and DM type, we further detected that the Asian group, T2DM group, and Asian group with T2DM all showed significant associations for all genetic models (ID vs. II: OR = 1.14, 95% CI: 1.01--1.29 for the Asian group, OR = 1.13, 95% CI: 1.00--1.24 for the T2DM group and OR = 1.14, 95% CI: 1.01--1.30 for the Asian group with T2DM, respectively; DD vs. II: OR = 1.54, 95% CI: 1.16--2.04 for the Asian group, OR = 1.39, 95% CI: 1.10--1.74 for the T2DM group and OR = 1.54, 95% CI: 1.14--2.08 for the Asian group with T2DM, respectively; Allele contrast: OR = 1.26, 95% CI: 1.10--1.45 for the Asian group, OR = 1.17, 95% CI: 1.04--1.32 for the T2DM group and OR = 1.26, 95% CI: 1.09--1.47 for the Asian group with T2DM, respectively; recessive model: OR = 1.42, 95% CI: 1.08--1.85 for the Asian group, OR = 1.24, 95% CI: 1.01--1.54 for the T2DM group and OR = 1.42, 95% CI: 1.07--1.88 for the Asian group with T2DM, respectively and dominant model: OR = 1.26, 95% CI: 1.08--1.47 for the Asian group, OR = 1.19, 95% CI: 1.05--1.36 for the T2DM group and OR = 1.26, 95% CI: 1.07--1.49 for the Asian group with T2DM, respectively). However, we did not find any significant effects for different genetic models in other subgroup. Further sensitivity analysis for HWE did not alter the pattern of results in both overall analysis and subgroup analysis.

3.5. Source of Heterogeneity and Publication Bias {#sec3dot5-ijerph-13-01142}
-------------------------------------------------

From [Table 3](#ijerph-13-01142-t003){ref-type="table"}, we found that the heterogeneity between studies was observed in overall comparisons as well as subgroup analyses. We estimated the source of heterogeneity in both dominant and recessive genetic models of the variant allele by ethnicity (Asian or Non-Asian), DM type (T1DM or T2DM), HWE (in HWE or not), and study design (case-control, cross-sectional, or cohort study design) by meta-regression analyses. It revealed that none of these four factors could influence significant between-study heterogeneity in genetic models for ACE I/D polymorphism: ethnicity (*p* = 0.78 for dominant model and *p* = 0.39 for recessive model), DM type (*p* = 0.59 for dominant model and *p* = 0.9 for recessive model), HWE (*p* = 0.26 for dominant model and *p* = 0.77 for recessive model), and study design (*p* = 0.06 for dominant model and *p* = 0.24 for recessive model).

The potential presence of publication bias was estimated by using a funnel plot of the evaluation of log-odds ratio for the genotype DD+ ID versus II against the reciprocal of its standard error ([Figure 3](#ijerph-13-01142-f003){ref-type="fig"}). As shown, we failed to find any significant funnel asymmetry to indicate publication bias. We further used the Egger regression asymmetry test and the Begg adjusted rank correlation test to estimate the publication bias of literatures included in the meta-analysis. As shown in [Table 4](#ijerph-13-01142-t004){ref-type="table"}, no publication bias was found for polymorphism and risk of DR in genetic models.

4. Discussion {#sec4-ijerph-13-01142}
=============

Why some diabetics develop retinopathy, whereas others do not, despite having long-term hyperglycemia, remains an undetermined question. Because known environmental factors do not fully explain this, researchers have sought the answer in the genetic background of the host \[[@B32-ijerph-13-01142]\]. The rennin-angiotensin-aldosterone system (RAAS) has been strongly implicated in the pathogenesis of progressive diabetes \[[@B64-ijerph-13-01142]\]. The RAAS is a critical regulator of sodium balance, extracellular fluid volume, vascular resistance, and, ultimately, arterial blood pressure by angiotensin II \[[@B61-ijerph-13-01142],[@B65-ijerph-13-01142],[@B66-ijerph-13-01142]\]. Thus, the RAAS serves as one of the most powerful regulators of arterial blood pressure and atherosclerosis and could be considered candidate genes involved in the pathogenesis of diabetic complications, including DR \[[@B67-ijerph-13-01142],[@B68-ijerph-13-01142]\]. As the gene-encoding components of the RAAS, the ACE gene plays an important role in the RAAS, which is a complicated regulatory network with intrinsic like extrinsic agonistic and antagonistic hormones. It has been increasingly recognized that ACE inhibition demonstrates function and tissue protection of considered organs, to improve eye function of patients with diabetes mellitus and reduce the development and progression of DR \[[@B69-ijerph-13-01142],[@B70-ijerph-13-01142]\]. In 1990, Rigat et al. described the polymorphism of the ACE gene based on the presence (insertion I) or absence (deletion D) of a 287 base pair element in intron 16 \[[@B11-ijerph-13-01142]\]. In plasma ACE levels, this genotype accounts for 47% of the total phenotypic variance in healthy individuals in a way that individuals with D alleles have an increased activity \[[@B11-ijerph-13-01142]\]. In addition, Danser et al. showed that the *ACE* I/D polymorphism also influences ACE tissue concentrations \[[@B9-ijerph-13-01142]\]. Numerous investigations into the potential role of ACE as a susceptibility gene for DR have been conducted over the past decades, with controversial results. Early meta-analyses attempted to reconcile these findings, but attempts to draw definite conclusions have been hindered by limited data, particularly when examining specific patient subgroups and increased relative studies \[[@B56-ijerph-13-01142],[@B57-ijerph-13-01142]\].

It is worth emphasizing that our current meta-analysis obtained several critically different conclusions from the previous reports \[[@B56-ijerph-13-01142],[@B57-ijerph-13-01142]\]. In Zhou's \[[@B56-ijerph-13-01142]\] report, they conducted a separate analysis of only the T2DM and T1DM groups, which showed that the ACE genotype has a non-significant association with DR, regardless of diabetic type. Lu et al. \[[@B57-ijerph-13-01142]\] performed the meta-analysis on only the Chinese population, without any subgroup analysis on DM type and ethnicity. However, from the present meta-analysis of 40 studies reported from 1994 to 2016 and comprising 10,168 subjects, we not only found the main effects of *ACE* I/D polymorphism on DR risk, but also found a significant relationship in the T2DM group. From the stratification analysis by ethnicity and DM type, we found that the *ACE* I/D polymorphism was significantly associated with DR risk in the T2DM and Asian groups, especially in the Asian group with T2DM. These findings may indicate that genetic factors may have more impact on the Asian population with T2DM, rather than on other subgroups like the T1DM and Non-Asian population.

We conducted a comprehensive meta-analysis on 40 published studies with 4252 diabetic retinopathy cases and 5916 controls relating the variant of the *ACE* I/D to the risk of DR, which can provide better ability to detect smaller effect sizes. Its strength was based on the accumulation of published data, giving greater information to detect significant differences. In order to estimate the power of the study, we used the Power and Precision 4 software to conduct the power calculation by respectively accumulating the frequency of ACE D allele in case and control groups from all studies, and the result showed the power of our study is 80.2%.

In this study, the effect of separate pairwise comparisons, allele contrast, and the dominant and recessive genetic models were evaluated. Substratification analysis by DM type andethnicity, and sensitivity analysis for studies not in HWE, was performed. In addition, we further evaluated the source of heterogeneity and the publication bias of included literatures.

Despite this, we still have some limits. In the meta-analysis, non-English/Chinese, non-indexed, and non-published studies literature was not reviewed, thus, some bias might be introduced \[[@B71-ijerph-13-01142]\]; only the unadjusted pooled ORs were calculated, since data for probable confounding factors that influence the estimates of associations (e.g., age, sex, BMI) were not provided; sampling variability and stratification in genetic association studies could be a possible confounding factor in the role of genetic markers. In addition, the risk effect may depend on the interaction with other risk factors: diabetes duration, HbA~1c~, blood pressure, total serum cholesterol, control of diabetes, and body mass index, all of which modulate the development of DR \[[@B3-ijerph-13-01142]\]. Furthermore, small numbers of individuals and inadequate information of lifestyle factors and dietary intake by the published studies limited our statistic power to fully investigate the gene-environment interactions \[[@B61-ijerph-13-01142]\]. Therefore, further well-designed large studies, particularly referring to GWAS and gene-environment interactions are warranted to determinate the real contribution of these polymorphisms to DR risk susceptibility and might further indicate the genetics of DR.

5. Conclusions {#sec5-ijerph-13-01142}
==============

In conclusion, the present meta-analysis finds an association between DR and *ACE* I/D polymorphism, especially in the Asian group with T2DM. Prospective and more genome-wide association studies (GWAS) are needed to clarify the real role of the ACE gene in determining susceptibility to DR.
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###### 

Characteristics of published studies included in the meta-analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (Reference)                                Year   Country       Design   Case   Control         HWE ^\#^         MAF \*      NOS (Stars \*)                                                                                     
  ------------------------------------------------- ------ ------------- -------- ------ --------------- ---------------- ----------- ---------------- ------------------------ ----------------- ------------------------ ------ ------ ---
  Marre et al. \[[@B14-ijerph-13-01142]\].          1994   France        CC       52     39.0 ± 14.0     20.0 ± 11.0      PDR         32               43.0 ± 18.0              22.0 ± 12.0       IDDM                     0.38   0.64   6

  Fujisawa et al. \[[@B15-ijerph-13-01142]\].       1995   Japan         CC       222    NR              NR               DR          45               NR                       NR                NIDDM                    0.84   0.36   5

  Tarnow et al. \[[@B16-ijerph-13-01142]\].         1995   Denmark       CC       155    40.9 ± 9.6      26.7 ± 7.9       PDR         67               42.7 ± 10.2              25.8 ± 8.5        IDDM                     0.05   0.57   6

  Nagi et al. \[[@B17-ijerph-13-01142]\].           1995   Britain       CC       271    50.6 ± 14.3\    27 (12--66)\     DR          376              38.3 ± 14.6\             16 (1--56)\       Healthy + IDDM + NIDDM   0.71   0.52   7
                                                                                         for IDDM\       for IDDM\                                     for IDDM\                for IDDM\                                                
                                                                                         66.8 ± 10.4\    11 (1--36)\                                   69.5 ± 11.1\             7 (1--45)\                                               
                                                                                         for NIDDM       for NIDDM                                     for NIDDM\               for NIDDM\                                               
                                                                                                                                                       NA for Healthy           NA for Healthy                                           

  Doi et al. \[[@B18-ijerph-13-01142]\].            1995   Japan         CC       362    61.8 (30--79)   \>10             DR          105              NA                       NA                Healthy                  0.25   0.34   4

  Yoshida et al. \[[@B19-ijerph-13-01142]\].        1996   Japan         CS       118    NA              NA               DR          50               NA                       NA                NIDDM                    0.59   0.31   4

  Gutie'rrez et al. \[[@B20-ijerph-13-01142]\].     1997   Spain         CC       68     61.9 ± 9.1      14.8 ± 5.7       DR          92               59.6 ± 10.3              12.1 ± 6.3        NIDDM                    0.97   0.61   6

  Liu et al. \[[@B21-ijerph-13-01142]\].            1997   China         CC       30     NA              NA               DR          198              NA for NDR\              NA                Healthy + NIDDM          0.92   0.27   4
                                                                                                                                                       34. 8 ± 5. 9\                                                                     
                                                                                                                                                       for Healthy                                                                       

  Hu et al. \[[@B22-ijerph-13-01142]\].             1998   China         CC       56     62.07 ± 1.21    11.68 ± 0.91     DR          81               56 .06 ± 1 .97\          4 .23 ± 0 .47\    Healthy + NIDDM          0.02   0.35   7
                                                                                                                                                       for NDR\                 for NDR                                                  
                                                                                                                                                       56 .86 ± 1 .46\                                                                   
                                                                                                                                                       for Healthy                                                                       

  Hanyu et al. \[[@B23-ijerph-13-01142]\].          1998   Japan         CC       45     60.0 ± 8.8\     18.2 ± 5.7\      DR          57               56.4 ± 5.1               NR                Healthy                  0.72   0.46   6
                                                                                         without DN\     without DN\                                                                                                                     
                                                                                         56.1 ± 10.5\    17.0 ± 6.0\                                                                                                                     
                                                                                         with DN         with DN                                                                                                                         

  Frost et al. \[[@B24-ijerph-13-01142]\].          1998   Germany       CS       79     30.1 ± 6.6      13.1 ± 8.1       DR          69               30.1 ± 6.6               13.1 ± 8.1        T1DM                     0.87   0.67   5

  Kimura et al. \[[@B25-ijerph-13-01142]\].         1998   Japan         CC       114    NA              NA               PDR         94               43.7 ± 15.4              NR                Healthy                  0.14   0.39   6

  Rabensteiner et al. \[[@B26-ijerph-13-01142]\].   1999   Austria       CC       94     47.2 ± 9.9      31.5 ± 8.2       PDR         81               47.7 ± 11.5              29.7 ± 8.8        T1DM                     0.37   0.44   6

  Solini et al. \[[@B27-ijerph-13-01142]\].         1999   Italy         CS       21     NA              NA               DR          181              NA                       NA                T2DM                     0.11   0.67   4

  Liao et al. \[[@B28-ijerph-13-01142]\].           1999   China         CC       68     51.9 ± 11.1\    9.35 ± 3.87\     BDR+PDR     76               53.2 ± 8.7 for NDR\      9.29 ± 5.17\      Healthy + T2DM           0.02   0.37   7
                                                                                         for BDR\        for BDR\                                      52.3 ± 9.9 for Healthy   for NDR                                                  
                                                                                         53.1 ± 8.8\     9.46 ± 5.11\                                                                                                                    
                                                                                         for PDR         for PDR                                                                                                                         

  Xiang et al. \[[@B29-ijerph-13-01142]\].          1999   China         CC       49     61.1 ± 10.5     7.1 ± 8.2        DR          162              53.2 ± 8.7\              9.29 ± 5.17\      Healthy + T2DM           0.28   0.38   7
                                                                                                                                                       for NDR\                 for NDR                                                  
                                                                                                                                                       52.3 ± 9.9\                                                                       
                                                                                                                                                       for Healthy                                                                       

  Wang et al. \[[@B30-ijerph-13-01142]\].           1999   China         CC       23     58.26 ± 9.57    5.21 ± 5.7       DR          172              59.0 ± 10.0\             4.0 ± 5.1\        Healthy + T2DM           0.00   0.39   7
                                                                                                                                                       for NDR\                 for NDR                                                  
                                                                                                                                                       64.9 ± 10.0\                                                                      
                                                                                                                                                       for Healthy                                                                       

  Liu et al. \[[@B31-ijerph-13-01142]\].            1999   China         CC       100    55 (36--90)     8.8 (0.5--18)    DR          164              53 (38--72)\             NA                Healthy + DM             0.21   0.40   5
                                                                                                                                                       for NDR\                                                                          
                                                                                                                                                       35 (20--58)\                                                                      
                                                                                                                                                       for Healthy                                                                       

  Van Ittersum et al. \[[@B32-ijerph-13-01142]\].   2000   New Zealand   CC       101    NA              NA               DR          151              NA                       NA                IDDM                     0.61   0.46   4

  Matsumoto et al. \[[@B33-ijerph-13-01142]\].      2000   Japan         CC       120    63.2 ± 10.4\    16.7 ± 7.6\      SDR+ADR     190              58.9 ± 12.1\             15.0 ± 6.6\       Healthy + T2DM           0.74   0.38   7
                                                                                         for SDR\        for SDR\                                      for NDR\                 for NDR                                                  
                                                                                         56.8 ± 11.9\    16.2 ± 9.1\                                   52.0 ± 1.0\                                                                       
                                                                                         for ADR         for ADR                                       for Healthy                                                                       

  Kankova et al. \[[@B34-ijerph-13-01142]\].        2000   Czech         CH       74     NA              NA               PDR         348              63.6 ± 13.4\             NA                Healthy + NIDDM          0.19   0.52   5
                                                                                                                                                       for Healthy                                                                       

  Liao et al. \[[@B35-ijerph-13-01142]\].           2000   China         CC       42     NA              NA               DR          178              54.83 ± 13.71\           0.5--30 for NDR   Healthy + T2DM           0.01   0.54   7
                                                                                                                                                       for NDR\                                                                          
                                                                                                                                                       48.71 ± 15.12\                                                                    
                                                                                                                                                       for Healthy                                                                       

  Yang et al. \[[@B36-ijerph-13-01142]\].           2000   China         CC       60     NA              NA               DR          137              NA                       NA                Healthy + NIDDM          0.21   0.32   4

  Araz et al. \[[@B37-ijerph-13-01142]\].           2001   Turkey        CS/CC    120    55.0 ± 8.0      11.2 ± 6.5       DR          257              51.0 ± 9.0 for NDR\      5.2 ± 5.1\        Healthy + T2DM           0.98   0.60   7
                                                                                                                                                       NA for Healthy           for NDR                                                  

  Viswanathan et al. \[[@B38-ijerph-13-01142]\].    2001   India         CC       86     56.7 + 8.9      13.4 + 6.9       DR          23               56.7 + 9.3               13.2 + 5.1        T2DM                     0.01   0.46   6

  Petrovic et al. \[[@B39-ijerph-13-01142]\].       2003   Slovenia      CC       124    65.6 ± 9.7      18.7 ± 9.1       DR          80               71.3 ± 7.0               16.8 ± 6.8        T2DM                     0.07   0.51   6

  Ha et al. \[[@B40-ijerph-13-01142]\].             2003   Korea         CS       180    NA              NA               DR          59               NA                       NA                T2DM                     0.07   0.37   4

  Crook et al. \[[@B41-ijerph-13-01142]\].          2003   USA           CH       46     NA              NA               DR          10               NA                       NA                T2DM                     0.24   0.80   4

  Agardh et al. \[[@B42-ijerph-13-01142]\].         2003   USA           CC       24     32 (24--37)     23 (16--31)      SDR         24               28.5 (22--57)            19.5 (10--56)     T1DM                     0.74   0.56   6

  Xu et al. \[[@B43-ijerph-13-01142]\].             2003   China         CC       58     62 ± 10         8 ± 6            DR          142              60 ± 12 for NDR\         8 ± 7 for NDR     Healthy + T2DM           0.03   0.35   7
                                                                                                                                                       59 ± 12 for Healthy                                                               

  Thomas et al. \[[@B55-ijerph-13-01142]\].         2003   China/Asia    CC       326    59.8 ± 11.4     6.3 (5.6--7.0)   DR          501              60.4 ± 9.3 for T2DM      6.0 (5.6-- 6.3)   T2DM                     0.38   0.33   6

  Wu et al. \[[@B44-ijerph-13-01142]\].             2004   China         CH       90     30.5 ± 4.3\     11.8 ± 2.4\      DR          294              36.8 ± 6.6\              24.3 ± 9.8\       T1DM + T2DM              0.22   0.57   8
                                                                                         for T1DR\       for T1DR\                                     for T1DM\                for T1DM\                                                
                                                                                         60.2 ± 8.3\     15.1 ± 4.7\                                   65.2 ± 3.2\              15.1 ± 5.0\                                              
                                                                                         for T2DR        for T2DR                                      for T2DM MI\             for T2DM MI\                                             
                                                                                                                                                       59.5 ± 1.2\              12.3 ± 3.3\                                              
                                                                                                                                                       for T2DM NMI             for T2DM NMI                                             

  Liao et al. \[[@B45-ijerph-13-01142]\].           2004   China         CC       44     NA              NA               BDR + PDR   21               NA                       NA                T2DM                     0.16   0.40   4

  Degirmenci et al. \[[@B46-ijerph-13-01142]\].     2005   Turkey        CC       57     NA              NA               DR          83               NA                       NA                T2DM                     0.61   0.54   4

  Chen et al. \[[@B47-ijerph-13-01142]\].           2005   China         CC       27     58.39 ± 9.47    NA               DR          319              55.43 ± 8.31 for NDR\    NA                Healthy + T2DM           0.39   0.63   5
                                                                                                                                                       NA for Healthy                                                                    

  Lee et al. \[[@B48-ijerph-13-01142]\].            2006   Korea         CC       130    53.1 ± 12.3     11.4 ± 3.7       DR          174              53.7 ± 12.9              9.4 ± 2.8         T2DM                     0.01   0.42   6

  Liang et al. \[[@B49-ijerph-13-01142]\].          2006   China         CC       82     63.41 ± 11.22   8.34 ± 6.36      DR          153              62.98 ± 11.87\           4.91 ± 4.76\      Healthy + T2DM           0.54   0.32   7
                                                                                                                                                       for NDR\                 for NDR                                                  
                                                                                                                                                       65.31 ± 9.77\                                                                     
                                                                                                                                                       for Healthy                                                                       

  Nikzamir et al. \[[@B50-ijerph-13-01142]\].       2010   Iran          CC       178    59.0 ± 8.7      13 (4--30)       DR          206              59.5 ± 8.2               11 (1--30)        T2DM                     0.29   0.46   6

  Li et al. \[[@B51-ijerph-13-01142]\].             2013   China         CC       207    62.4 ± 7.8      14.6 ± 7.5       DR          302              59.5 ± 8.2\              15.0 ± 4.3\       Healthy + T2DM           0.02   0.50   7
                                                                                                                                                       for NDR\                 for NDR                                                  
                                                                                                                                                       75.5 ± 2.8\                                                                       
                                                                                                                                                       for Healthy                                                                       

  Narne et al. \[[@B54-ijerph-13-01142]\].          2016   India         CC       149    52.7 ± 7.3      14.7 ± 4.7       DR          162              53.4 ± 5.4               15.9 ± 5.6        T2DM                     0.05   0.40   6
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The reference was referred to the reference numbers in this study; ^**\#**^ Hardy-Weinberg equilibrium (HWE) test and **\*** the minor allele frequency (MAF) were calculated in the control group for each study; NR, not reported; NA, not available; CC, case-control; CS, cross-sectional; CH cohort; DR, diabetes retinopathy; BDR, background diabetes retinopathy; SDR, simple diabetes retinopathy; ADR, advanced diabetic retinopathy; PDR, proliferative diabetes retinopathy; NDR, non-diabetes retinopathy; DN, diabetes nephropathy; DM, diabetes mellitus; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; IDDM, insulin dependent diabetes mellitus; NIDDM, non-insulin dependent diabetes mellitus; MI, myocardial infarct; NMI, non-myocardial infract.
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###### 

The details on *ACE* I/D (angiotensin-converting enzyme insertion/deletion) polymorphism allele/genotype prevalence.

  Author (Reference)                                Prevalence of *ACE* I/D Genotype   Prevalence of Allele Frequency                                                                                  
  ------------------------------------------------- ---------------------------------- -------------------------------- ---------- ---------- ---------- ---------- ---------- ------------ ---------- ----------
  Marre et al. \[[@B14-ijerph-13-01142]\].          8                                  3                                28         17         16         12         44         23           60         41
  Fujisawa et al. \[[@B15-ijerph-13-01142]\].       87                                 19                               102        20         33         6          276        58           168        32
  Tarnow et al. \[[@B16-ijerph-13-01142]\].         29                                 16                               74         25         52         26         132        57           178        77
  Nagi et al. \[[@B17-ijerph-13-01142]\].           74                                 88                               120        184        77         104        268        360          274        392
  Doi et al. \[[@B18-ijerph-13-01142]\].            132                                48                               179        42         51         15         443        138          281        72
  Yoshida et al. \[[@B19-ijerph-13-01142]\].        45                                 23                               51         23         22         4          141        69           95         31
  Gutie'rrez et al. \[[@B20-ijerph-13-01142]\].     6                                  14                               30         44         32         34         42         72           94         112
  Liu et al. \[[@B21-ijerph-13-01142]\].            10                                 105                              8          78         12         15         28         288          32         108
  Hu et al. \[[@B22-ijerph-13-01142]\].             29                                 39                               15         27         12         15         73         105          39         57
  Hanyu et al. \[[@B23-ijerph-13-01142]\].          21                                 17                               18         27         6          13         60         61           30         53
  Frost et al. \[[@B24-ijerph-13-01142]\].          23                                 8                                25         30         31         31         71         46           87         92
  Kimura et al. \[[@B25-ijerph-13-01142]\].         48                                 38                               47         38         19         18         143        114          85         74
  Rabensteiner et al. \[[@B26-ijerph-13-01142]\].   11                                 23                               46         44         37         14         68         90           120        72
  Solini et al. \[[@B27-ijerph-13-01142]\].         4                                  25                               16         71         1          85         24         121          18         241
  Liao et al. \[[@B28-ijerph-13-01142]\].           33                                 35                               21         26         14         15         87         96           49         56
  Xiang et al. \[[@B29-ijerph-13-01142]\].          12                                 65                               23         70         14         27         47         200          51         124
  Wang et al. \[[@B30-ijerph-13-01142]\].           9                                  75                               8          61         6          36         26         211          20         133
  Liu et al. \[[@B31-ijerph-13-01142]\].            33                                 63                               38         71         29         30         104        197          96         131
  Van Ittersum et al. \[[@B32-ijerph-13-01142]\].   29                                 45                               47         72         25         34         105        162          97         140
  Matsumoto et al. \[[@B33-ijerph-13-01142]\].      41                                 75                               53         87         26         28         135        237          105        143
  Kankova et al. \[[@B34-ijerph-13-01142]\].        14                                 75                               39         186        21         87         67         336          81         360
  Liao et al. \[[@B35-ijerph-13-01142]\].           11                                 46                               18         72         13         60         40         164          44         192
  Yang et al. \[[@B36-ijerph-13-01142]\].           22                                 60                               14         66         24         11         58         186          62         88
  Araz et al. \[[@B37-ijerph-13-01142]\].           20                                 42                               62         124        38         91         102        208          138        306
  Viswanathan et al. \[[@B38-ijerph-13-01142]\].    17                                 10                               45         5          24         8          79         25           93         21
  Petrovic et al. \[[@B39-ijerph-13-01142]\].       28                                 23                               63         32         33         25         119        78           129        82
  Ha et al. \[[@B40-ijerph-13-01142]\].             48                                 20                               85         34         47         5          181        74           179        44
  Crook et al. \[[@B41-ijerph-13-01142]\].          5                                  1                                27         2          14         7          37         4            55         16
  Agardh et al. \[[@B42-ijerph-13-01142]\].         4                                  5                                11         11         9          8          19         21           29         27
  Xu et al. \[[@B43-ijerph-13-01142]\].             11                                 66                               31         53         16         23         53         185          63         99
  Thomas et al. \[[@B55-ijerph-13-01142]\].         157                                231                              129        212        40         58         443        674          209        328
  Wu et al. \[[@B44-ijerph-13-01142]\].             11                                 60                               45         134        34         100        67         254          113        334
  Liao et al. \[[@B45-ijerph-13-01142]\].           19                                 9                                16         7          9          5          54         25           34         17
  Degirmenci et al. \[[@B46-ijerph-13-01142]\].     6                                  19                               34         39         17         25         46         77           68         89
  Chen et al. \[[@B47-ijerph-13-01142]\].           3                                  39                               5          155        19         125        11         233          43         405
  Lee et al. \[[@B48-ijerph-13-01142]\].            47                                 67                               69         68         14         39         163        202          97         146
  Liang et al. \[[@B49-ijerph-13-01142]\].          26                                 73                               36         63         20         17         88         209          76         97
  Nikzamir et al. \[[@B50-ijerph-13-01142]\].       47                                 56                               73         110        58         40         167        222          189        190
  Li et al. \[[@B51-ijerph-13-01142]\].             52                                 64                               120        172        35         66         224        300          190        304
  Narne et al. \[[@B54-ijerph-13-01142]\].          46                                 64                               76         66         27         32         168        194          130        130
  **Total**                                         **1278**                           **1854**                         **1947**   **2668**   **1027**   **1394**   **4503**   **63,762**   **4001**   **5456**
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###### 

Summary ORs and heterogeneity results for associations between the ACE I/D polymorphism and DR (diabetic retinopathy).

  Genetic Model         Group         Sensitivity ^\#^   Studies      OR           95% CI       *p* \*   *I*^2^ (%)
  --------------------- ------------- ------------------ ------------ ------------ ------------ -------- ------------
  ID vs. II             All studies   All                40           1.14         1.00--1.30   0.02     33.8
  Sensitivity           32            1.08               0.97--1.21   0.13         22.60                 
  Non-Asian             All           15                 1.04         0.86--1.25   0.09         35.30    
  Sensitivity           15            1.04               0.86--1.25   0.09         35.30                 
  Asian                 All           25                 1.14         1.01--1.29   0.05         34.50    
  Sensitivity           17            1.11               0.96--1.29   0.32         11.50                 
  TIDM                  All           8                  1.00         0.64--1.56   0.05         50.30    
  Sensitivity           8             1.00               0.64--1.56   0.05         50.30                 
  T2DM                  All           33                 1.13         1.00--1.24   0.05         31.20    
  Sensitivity           26            1.07               1.00--1.21   0.30         11.40                 
  Non-Asian with T1DM   All           7                  0.98         0.84--1.14   0.04         55.40    
  Sensitivity           7             0.98               0.84--1.14   0.04         55.40                 
  Non-Asian with T2DM   All           9                  1.03         0.96--1.10   0.49         0.00     
  Sensitivity           9             1.03               0.96--1.10   0.49         0.00                  
  Asian with T1DM       All           1                  1.13         0.87--1.46   NA           NA       
  Sensitivity           1             1.13               0.87--1.46   NA           NA                    
  Asian with T2DM       All           24                 1.14         1.01--1.30   0.05         36.10    
  Sensitivity           16            1.11               1.00--1.29   0.29         13.90                 
  DD vs. II             All studies   All                40           1.38         1.11--1.71   0.00     62.3
  Sensitivity           32            1.46               1.15--1.87   0.00         62.20                 
  Non-Asian             All           15                 1.14         0.81--1.60   0.01         55.50    
  Sensitivity           15            1.14               0.81--1.60   0.01         55.50                 
  Asian                 All           25                 1.54         1.16--2.04   0.00         65.30    
  Sensitivity           17            1.80               1.30--2.51   0.00         63.20                 
  TIDM                  All           8                  1.08         0.63--1.87   0.01         61.70    
  Sensitivity           8             1.08               0.63--1.87   0.01         61.70                 
  T2DM                  All           33                 1.39         1.10--1.74   0.00         61.80    
  Sensitivity           26            1.58               1.20--2.07   0.00         66.20                 
  Non-Asian with T1DM   All           7                  1.09         0.92--1.30   0.09         44.90    
  Sensitivity           7             1.09               0.92--1.30   0.09         44.90                 
  Non-Asian with T2DM   All           9                  1.06         0.96--1.18   0.26         20.20    
  Sensitivity           9             1.06               0.96--1.18   0.26         20.20                 
  Asian with T1DM       All           1                  0.99         0.64--1.53   NA           NA       
  Sensitivity           1             0.99               0.64--1.53   NA           NA                    
  Asian with T2DM       All           24                 1.54         1.14--2.08   0.00         66.70    
  Sensitivity           16            1.83               1.27--2.63   0.00         65.80                 
  Allele contrast       All studies   All                40           1.17         1.05--1.30   0        64.7
  Sensitivity           32            1.19               1.05--1.35   0.00         65.40                 
  Non-Asian             All           15                 1.02         0.86--1.22   0.00         62.10    
  Sensitivity           15            1.02               0.86--1.22   0.00         62.10                 
  Asian                 All           25                 1.26         1.10--1.45   0.00         65.40    
  Sensitivity           17            1.35               1.15--1.59   0.00         64.00                 
  TIDM                  All           8                  1.03         0.78--1.34   0.01         61.00    
  Sensitivity           8             1.03               0.78--1.34   0.01         61.00                 
  T2DM                  All           33                 1.17         1.04--1.32   0.00         64.90    
  Sensitivity           26            1.22               1.06--1.40   0.00         66.50                 
  Non-Asian with T1DM   All           7                  1.02         0.89--1.16   0.01         65.40    
  Sensitivity           7             1.02               0.89--1.16   0.01         65.40                 
  Non-Asian with T2DM   All           9                  1.01         0.92--1.10   0.02         54.80    
  Sensitivity           9             1.01               0.92--1.10   0.02         54.80                 
  Asian with T1DM       All           1                  0.96         0.76--1.23   NA           NA       
  Sensitivity           1             0.96               0.76--1.23   NA           NA                    
  Asian with T2DM       All           24                 1.26         1.09--1.47   0.00         66.90    
  Sensitivity           16            1.36               1.14--1.63   0.00         66.30                 
  Recessive model       All studies   All                40           1.24         1.02--1.51   0        67.6
  Sensitivity           32            1.33               1.07--1.66   0.00         69.20                 
  Non-Asian             All           15                 1.03         0.79--1.35   0.00         59.70    
  Sensitivity           15            1.03               0.79--1.35   0.00         59.70                 
  Asian                 All           25                 1.42         1.08--1.85   0.00         71.10    
  Sensitivity           17            1.73               1.24--2.41   0.00         71.90                 
  TIDM                  All           8                  1.09         0.86--1.39   0.09         43.20    
  Sensitivity           8             1.09               0.86--1.39   0.09         43.20                 
  T2DM                  All           33                 1.24         1.01--1.54   0.00         69.50    
  Sensitivity           26            1.36               1.06--1.74   0.00         71.90                 
  Non-Asian with T1DM   All           7                  1.09         0.92--1.30   0.09         44.90    
  Sensitivity           7             1.09               0.92--1.30   0.09         44.90                 
  Non-Asian with T2DM   All           9                  1.00         0.75--1.25   0.00         67.20    
  Sensitivity           9             1.00               0.75--1.25   0.00         67.20                 
  Asian with T1DM       All           1                  0.76         0.42--1.42   NA           NA       
  Sensitivity           1             0.76               0.42--1.42   NA           NA                    
  Asian with T2DM       All           24                 1.42         1.07--1.88   0.00         71.80    
  Sensitivity           16            1.76               1.23--2.51   0.00         72.90                 
  Dominant model        All studies   All                40           1.21         1.06--1.38   0.01     37.8
  Sensitivity           32            1.17               1.06--1.31   0.05         30.50                 
  Non-Asian             All           15                 1.15         0.97--1.37   0.18         25.30    
  Sensitivity           15            1.15               0.97--1.37   0.18         25.30                 
  Asian                 All           25                 1.26         1.08--1.47   0.03         37.60    
  Sensitivity           17            1.25               1.09--1.42   0.02         19.80                 
  TIDM                  All           8                  1.03         0.66--1.61   0.02         57.30    
  Sensitivity           8             1.03               0.66--1.61   0.02         57.30                 
  T2DM                  All           33                 1.19         1.05--1.36   0.04         32.20    
  Sensitivity           26            1.16               1.04--1.29   0.20         18.60                 
  Non-Asian with T1DM   All           7                  1.00         0.90--1.11   0.01         63.00    
  Sensitivity           7             1.00               0.90--1.11   0.01         63.00                 
  Non-Asian with T2DM   All           9                  1.02         0.98--1.07   0.67         0.00     
  Sensitivity           9             1.02               0.98--1.07   0.67         0.00                  
  Asian with T1DM       All           1                  1.05         0.89--1.25   NA           NA       
  Sensitivity           1             1.05               0.89--1.25   NA           NA                    
  Asian with T2DM       All           24                 1.26         1.07--1.49   0.02         40.20    
  Sensitivity           16            1.24               1.08--1.43   0.17         25.00                 

^\#^ Sensitivity analysis for HWE; \* test for heterogeneity; random-effects model was used when *p* value for heterogeneity test \< 0.05 and *I*^2^ \> 50%; otherwise, fixed-effects model was used.
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###### 

The results of publication bias test by Egger and Begg test.

  Sub Group   Egger Test   Begg Test          
  ----------- ------------ ----------- ------ ------
  all study   0.14         0.71        0.47   0.63
  T1DM        0.96         0.86        1.00   1.00
  T2DM        0.06         0.62        0.25   0.46
  Non-Asian   0.08         0.12        0.11   0.43
  Asian       0.09         0.12        0.34   0.18

[^1]: These authors contributed equally to this work.
